Primary information |
---|
sequence ID | Seq_2051 |
Peptide sequence | FAEEGKKLVAASQAALGL |
CancerPDF_ID | CancerPDF_ID9542, |
PMID | 21533267 |
Protein Name | Serum albumin |
UniprotKB Entry Name | ALBU_HUMAN |
Fluid | Serum |
M/Z | 601.66 |
Charge | 3 |
Profiling Technique | LC-MS |
Peptide Identification technique | LC/MS/MS |
Quantification Technique | Multiple Reaction Monitoring |
Labelled/Label Free | Label Free |
FDR | 1.49 |
CancerPDF_ID | CancerPDF_ID9542, |
p-Value | NA |
Software | MASCOT |
Length | 18 |
Cancer Type | Lung adenocarcinoma |
Database | Swissprot Database (57.4) |
Modification | NA |
Number of Patients | 62 lung adenocarcinoma and 30 healthy control |
Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
Validation | MRM-based validation of 19 candidates |
Sensitivity | NA |
Specificity | NA |
Accuracy | NA |
Peptide Atlas | NA |
IEDB | NA |